Phase II Trial of Oral GLP-1 Agonist VCT220 for Obesity Treatment Reported | Retatrutide News

A phase II trial of VCT220, an oral GLP-1 receptor agonist, was reported for obesity treatment. This trial highlights ongoing research into more conveni...
Clinical Trials · October 25, 2026